India Orders Post-Marketing Data For Pfizer’s Champix
This article was originally published in PharmAsia News
India's drug regulator has instructed U.S. drug maker Pfizer's Indian subsidiary to submit post-marketing data on the impact of its Champix (varenicline) drug to help smokers quit. Although Indian physicians have not reported seeing problems with use of the psychotropic drug, Pfizer was instructed to complete its post-marketing study by May of next year, followed by regular updates. A Pfizer Ltd. official said the study already is underway with 300 patients at 21 sites. India's post-marketing surveillance regulations usually are followed only if the government specifically orders them. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.